跳至主要内容
临床试验/NCT01045486
NCT01045486撤回不适用

A Double Blind, Randomized, Placebo-Controlled, Crossover Study to Compare the Effectiveness of Probiotics on Atopic Dermatitis With Cow Milk Allergy in Korean Infants

Soonchunhyang University Hospital0 个研究点目标入组 36 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
入组人数
36
主要终点
Check SCORAD index for severity of atopic dermatitis, symptom diary, blood cytokine and chemokine (IL-4,IL-6, IL-10, IL-13, total IgE, IFN-γ, TGF-β, TNF-α, and IgG4) after drug administration

研究概览

简要总结

There is not enough evidence to support the use of probiotics for prevention or treatment of AD in children in clinical practice.

The purpose of this study is to determine whether probiotics is effective in the treatment of atopic dermatitis with cow milk allergy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Months 至 2 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Under the 2 years old, 36 children
  • Mild to moderate atopic dermatitis with cow milk allergy
  • Volunteers who agreed by their parents.
  • The severity of their disease was assessed by modified SCORAD index

排除标准

  • Severe atopic dermatitis
  • Patients on systemic steroids, immune-suppression or Korean herbal medicine during the previous 6 weeks
  • Anaphylaxis, Angioedema, or severe allergic reaction to the cow milk
  • Chronic diarrhea

研究组 & 干预措施

Group A

Active Comparator

Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.

干预措施: ATP mixed probiotics (Drug)

Group B

Placebo Comparator

Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.

干预措施: Placebo (Drug)

结局指标

主要结局

Check SCORAD index for severity of atopic dermatitis, symptom diary, blood cytokine and chemokine (IL-4,IL-6, IL-10, IL-13, total IgE, IFN-γ, TGF-β, TNF-α, and IgG4) after drug administration

时间窗: 6 weeks after patient recruitment

次要结局

  • Check SCORAD index for severity of atopic dermatitis, symptom diary, blood cytokine and chemokine (IL-4,IL-6, IL-10, IL-13, total IgE, IFN-γ, TGF-β, TNF-α, and IgG4) after drug administration(6 weeks after wash-out period)

研究者

申办方类型
Other

相似试验

已完成
不适用
Placebo controlled double blind randomized Phase II Clinical Trial of sodium pyruvate on lactic acidosis associated with mitochondrial disorders (MELAS/MELA)MELAS/MELA
JPRN-UMIN000025772Japan Agency of Medical Research and Development15
进行中(未招募)
不适用
Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women”Estudio doble ciego controlado con placebo de la eficacia, seguridad y tolerancia del raloxifeno como tratamiento coadyuvante de los síntomas negativos de la esquizofrenia en mujeres postmenopáusicas.Trastorno esquizofrénico
EUCTR2004-004281-32-ESSan Joan de Déu. Serveis de Salut Mental
进行中(未招募)
不适用
Double Blind Placebo Controlled Clinical Investigation into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients with Severe Pulmonary Arterial HypertensioYHA Class III and IV patients with severe Pulmonary Arterial HypertensioMedDRA version: 14.1Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2004-003236-59-ITnited Therapeutics Corporation220
已完成
2 期
Placebo controlled, double-blind study for efficacy of two herbal supplements (Trigonella foenum-graecum Seed Extract and Coccinia Grandis Extract) for Normalizing Elevated (pre-diabetic) blood Glucose and improving Insulin Sensitivity - a 3 arm study.diabetespre-diabetesMetabolic and Endocrine - DiabetesAlternative and Complementary Medicine - Herbal remedies
ACTRN12618000031268Evidence Sciences Pty. Ltd.79
招募中
3 期
Ginger caplets in Post operative nausea and vomiting
CTRI/2012/10/003063The Himalaya Drug Company50